Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category
Neuroscience Neurology process Neural Signal Transduction

Human SFN (14-3-3 sigma) knockout HeLa cell pellet (ab279108)

Price and availability

670 ₸

Availability

Order now and get it on Tuesday March 09, 2021

Human SFN (14-3-3 sigma) knockout HeLa cell pellet (ab279108)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)

You may also be interested in

Product image
Human HES4 knockout A549 cell line (ab267134)
Product image
Anti-Dab1 antibody [EP2248Y] (ab68461)
Product image
Anti-NDRG1 antibody - BSA and Azide free (Capture) (ab272294)
Product image
Anti-Slit1 antibody (ab10984)

Overview

  • Product name

    Human SFN (14-3-3 sigma) knockout HeLa cell pellet
    See all 14-3-3 sigma/SFN kits
  • Product overview

    Abcam’s knockout cell pellets give you access to native proteins, without the need to culture cells. Our knockout cell pellets are prepared from our single-gene knockout cell lines and provide an additional offering to our cell lysates.

    Cells are snap-frozen to provide high quality pellets that are suitable for extraction with alternative lysis buffers or for preparation of lysates from subcellular fractions. Our knockout cell pellets are suitable for a variety of applications, including PCR, gene expression profiling and DNA library preparation.

  • Parental Cell Line

    HeLa
  • Organism

    Human
  • Mutation description

    Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 2 bp deletion in exon 1.
  • Passage number

  • Knockout validation

    Sanger Sequencing, Western Blot (WB)
  • Notes

    Pellet size: 5 million cells/vial.

    This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

  • Tested applications

    Suitable for: WBmore details

Properties

  • Storage instructions

    Store at -80°C. Please refer to protocols.
  • Components 1 kit
    Human SFN knockout HeLa cell pellet 1 vial
    Human wild-type HeLa cell pellet 1 vial
  • Research areas

    • Neuroscience
    • Neurology process
    • Neural Signal Transduction
    • Signal Transduction
    • Adapters
    • Cytoplasmic
    • Neuroscience
    • Cell Type Marker
    • Neuron marker
    • Synapse marker
    • Stem Cells
    • Signaling Pathways
    • Wnt
    • 14-3-3
  • Cell type

    epithelial
  • Disease

    Adenocarcinoma
  • Gender

    Female
  • STR Analysis

    Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10

Target

  • Function

    Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. When bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway. May also regulate MDM2 autoubiquitination and degradation and thereby activate p53/TP53.
    p53-regulated inhibitor of G2/M progression.
  • Tissue specificity

    Present mainly in tissues enriched in stratified squamous keratinizing epithelium.
  • Sequence similarities

    Belongs to the 14-3-3 family.
  • Post-translational
    modifications

    Ubiquitinated. Ubiquitination by RFFL induces proteasomal degradation and indirectly regulates p53/TP53 activation.
  • Cellular localization

    Cytoplasm. Nucleus. Secreted. May be secreted by a non-classical secretory pathway.
  • Target information above from: UniProt accession P31947 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Alternative names

    • 14 3 3 protein sigma
    • 14-3-3 protein sigma
    • 1433S_HUMAN
    • Epithelial cell marker protein 1
    • Er
    • HME 1
    • HME1
    • MGC143283
    • Mkrn3
    • Mme1
    • OTTHUMP00000004242
    • RP23 137L22.11
    • SFN
    • SFN protein
    • Stratifin
    • YWHAS
    see all

Properties

  • Storage instructions

    Store at -80°C. Please refer to protocols.
  • Components 1 kit
    Human SFN knockout HeLa cell pellet 1 vial
    Human wild-type HeLa cell pellet 1 vial
  • Research areas

    • Neuroscience
    • Neurology process
    • Neural Signal Transduction
    • Signal Transduction
    • Adapters
    • Cytoplasmic
    • Neuroscience
    • Cell Type Marker
    • Neuron marker
    • Synapse marker
    • Stem Cells
    • Signaling Pathways
    • Wnt
    • 14-3-3
  • Cell type

    epithelial
  • Disease

    Adenocarcinoma
  • Gender

    Female
  • STR Analysis

    Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10

Images

  • Western blot - Human SFN (14-3-3 sigma) knockout HeLa cell pellet (ab279108)
    Western blot - Human SFN (14-3-3 sigma) knockout HeLa cell pellet (ab279108)

    Lane 1: Wild-type HeLa cell lysate (20 µg)

    Lane 2: SFN knockout HeLa cell lysate (20 µg)

    Lane 3: A431 cell lysate (20 µg)

    Lanes 1-3: Merged signal (red and green). Green - ab14123 observed at 28 kDa. Red - loading control, ab52866 observed at 50 kDa.

    ab14123 Anti-14-3-3 sigma/SFN antibody [1433S01] was shown to specifically react with 14-3-3 sigma/SFN in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261779 (knockout cell lysate ab257288) was used. Wild-type and 14-3-3 sigma/SFN knockout samples were subjected to SDS-PAGE. ab14123 and Anti-alpha Tubulin antibody [EP1332Y] - Loading Control (ab52866) were incubated overnight at 4°C at 1 in 200 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.

  • Sanger Sequencing - Human SFN (14-3-3 sigma) knockout HeLa cell pellet (ab279108)
    Sanger Sequencing - Human SFN (14-3-3 sigma) knockout HeLa cell pellet (ab279108)

    Allele-1: 2 bp deletion in exon 1

     

  • Sanger Sequencing - Human SFN (14-3-3 sigma) knockout HeLa cell pellet (ab279108)
    Sanger Sequencing - Human SFN (14-3-3 sigma) knockout HeLa cell pellet (ab279108)

    Allele-2: 1 bp deletion in exon 1

     

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

  •  
  • Product image

    Anti-Semaphorin 4D/CD100 antibody [EPR23866-69] (ab275393)

  •  
  • Product image

    Anti-SNRPD3/Sm-D3 antibody [EPR7676] - BSA and Azide free (ab232464)

  •  
  • Goat Anti-Donkey IgG H&L (HRP) (ab98825)

  •  
  • Donkey F(ab) Anti-Goat IgG H&L (TRITC) (ab6522)

  •  
  • Product image

    Rat TIMP-2 ELISA Kit (ab213923)

  •  
  • Product image

    Recombinant Human JunB protein (ab152484)

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.